| Text Messaging Reminders for Influenza Vaccine in Primary Care (NCT01892631) | London School of Hygiene and Tropical Medicine | 2013-09-01 |
| Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women (NCT01816464) | University of Witwatersrand, South Africa | 2013-09-01 |
| H7N9 Mix and Match With AS03 and MF59 in Healthy Adults (NCT01942265) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-09-01 |
| Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age (NCT01934127) | GlaxoSmithKline | 2013-08-26 |
| Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry (NCT01945424) | Sanofi Pasteur, a Sanofi Company | 2013-08-16 |
| Japanese Pediatric H5N1 Vaccine Study (NCT01911754) | Alachua Government Services, Inc. | 2013-08-01 |
| Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers (NCT01987011) | Green Cross Corporation | 2013-08-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older (NCT01878825) | GlaxoSmithKline | 2013-07-18 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older (NCT01878812) | GlaxoSmithKline | 2013-07-11 |
| Influenza Diagnosis, Treatment and Surveillance With Xpert Flu (NCT01947049) | Johns Hopkins University | 2013-07-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older (NCT01884519) | GlaxoSmithKline | 2013-07-01 |
| Use of Probiotics to Prevent Influenza (NCT01720329) | McMaster University | 2013-07-01 |
| Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14) (NCT01893177) | Crucell Holland BV | 2013-07-01 |
| The Benefit and Harm of Fever Suppression by Antipyretics in Influenza (NCT01891084) | The University of Hong Kong | 2013-07-01 |
| Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda (NCT01916759) | Emory University | 2013-06-01 |
| Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine (NCT02819115) | Butantan Institute | 2013-06-01 |
| A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly (NCT01906593) | Centers for Disease Control and Prevention, China | 2013-06-01 |
| Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza (NCT01793883) | Biota Scientific Management Pty Ltd | 2013-05-01 |
| Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age (NCT01857206) | Novartis Vaccines | 2013-05-01 |
| Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women (NCT01812980) | University of Witwatersrand, South Africa | 2013-05-01 |
| Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults (NCT01859143) | MedImmune LLC | 2013-05-01 |
| Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above (NCT01867021) | Novartis | 2013-05-01 |
| Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal (NCT01854632) | PATH | 2013-05-01 |
| Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age (NCT01825200) | Protein Sciences Corporation | 2013-03-01 |
| H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older (NCT01774032) | Alachua Government Services, Inc. | 2013-03-01 |
| Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza (NCT01610245) | Romark Laboratories L.C. | 2013-03-01 |
| Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus (NCT01406418) | Crucell Holland BV | 2013-02-01 |
| Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections (NCT01779570) | Chinese University of Hong Kong | 2013-02-01 |
| A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh (NCT01797029) | PATH | 2013-02-01 |
| High-Dose Influenza Vaccine in Nursing Homes (NCT01815268) | Insight Therapeutics, LLC | 2013-02-01 |
| Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses (NCT01756950) | Crucell Holland BV | 2013-01-01 |
| Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States (NCT02019732) | GlaxoSmithKline | 2013-01-01 |
| Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (NCT01773928) | Alachua Government Services, Inc. | 2013-01-01 |
| Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations (NCT01746082) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-01-01 |
| Post-License Safety Evaluation of Influenza Virus Vaccine (NCT02136017) | Sichuan Center for Disease Control and Prevention | 2013-01-01 |
| Pilot Text Message for Influenza Vaccination (NCT01761734) | Columbia University | 2013-01-01 |
| Testing the AVI-7100 Flu Drug in Healthy Volunteers (NCT01747148) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-12-08 |
| Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old (NCT01730378) | GlaxoSmithKline | 2012-12-05 |
| The Human Mucosal Immune Responses to Influenza Virus (SLVP026) (NCT03023553) | Stanford University | 2012-12-01 |
| Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One (NCT01546935) | University of Oxford | 2012-12-01 |
| Intracutaneous Delivery of Varied Dose Volumes of Saline (NCT01767337) | FluGen Inc | 2012-12-01 |
| Protecting Pregnant Women From Infectious Diseases (NCT01761799) | Emory University | 2012-12-01 |
| T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza (NCT01728753) | MDVI, LLC | 2012-11-01 |
| The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine (NCT01736709) | Sinovac Biotech Co., Ltd | 2012-11-01 |
| Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza (NCT01740063) | Ansun Biopharma, Inc. | 2012-11-01 |
| A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old (NCT01755364) | Adimmune Corporation | 2012-11-01 |
| Live Versus Inactivated Influenza Vaccine Study in Hutterite Children (NCT01653015) | McMaster University | 2012-11-01 |
| A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects (NCT01759654) | Adimmune Corporation | 2012-10-24 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 (NCT01702454) | GlaxoSmithKline | 2012-10-06 |
| The Influence of Chronic CMV Infection on Influenza Vaccine Responses (NCT02134184) | Stanford University | 2012-10-01 |
| Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024) (NCT03023683) | Stanford University | 2012-10-01 |
| Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years (NCT01712984) | Sanofi Pasteur, a Sanofi Company | 2012-10-01 |
| Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK (NCT01715792) | GlaxoSmithKline | 2012-10-01 |
| T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012 (NCT03022435) | Stanford University | 2012-10-01 |
| Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine (NCT01767896) | UMN Pharma Inc. | 2012-10-01 |
| Routes of Immunization and Flu Immune Responses (NCT01707602) | Assistance Publique - Hôpitaux de Paris | 2012-10-01 |
| Panama and El Salvador Children's Oseltamivir Study (NCT01690637) | Centers for Disease Control and Prevention | 2012-09-01 |
| Evaluating Immune Response to Seasonal FluMist in Healthy Adults (NCT01673425) | National Center for Occupational Health and Infection Control | 2012-09-01 |
| Self-Administered Nasal Influenza Feasibility Study (NCT01933048) | Henry M. Jackson Foundation for the Advancement of Military Medicine | 2012-09-01 |
| Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) (NCT01691326) | Sanofi Pasteur, a Sanofi Company | 2012-09-01 |
| Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine (NCT01719783) | PATH | 2012-09-01 |
| High Dose Influenza Vaccine in Nursing Home - Pilot Study (NCT01720277) | Insight Therapeutics, LLC | 2012-09-01 |
| Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women (NCT01527825) | University of Witwatersrand, South Africa | 2012-09-01 |
| Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 (NCT01658800) | VaxInnate Corporation | 2012-09-01 |
| Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults. (NCT01691339) | Sanofi Pasteur, a Sanofi Company | 2012-09-01 |
| Safety Study of an Oral Vaccine to Prevent Seasonal Influenza (NCT01688297) | Vaxart | 2012-09-01 |
| Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children (NCT01662583) | Columbia University | 2012-09-01 |
| ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses (NCT01682369) | University of Oxford | 2012-09-01 |
| Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age (NCT01659086) | GlaxoSmithKline | 2012-08-22 |
| Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects (NCT01752881) | Adimmune Corporation | 2012-08-01 |
| Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients (NCT01584908) | University of Alberta | 2012-08-01 |
| Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza (NCT01719874) | Theraclone Sciences, Inc. | 2012-08-01 |
| Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season (NCT01649713) | Fluart Innovative Vaccine Ltd, Hungary | 2012-08-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults (NCT01626820) | GlaxoSmithKline | 2012-07-19 |
| A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above (NCT01607112) | GlaxoSmithKline | 2012-07-10 |
| Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine (NCT01582633) | University of Sao Paulo General Hospital | 2012-07-01 |
| Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above (NCT01640327) | Novartis Vaccines | 2012-07-01 |
| Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (NCT01631110) | Crucell Holland BV | 2012-07-01 |
| Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains (NCT01631071) | Crucell Holland BV | 2012-07-01 |
| Influenza Burden Assessment in the United States, July1997 - up to April 2009 (NCT01599390) | GlaxoSmithKline | 2012-07-01 |
| Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above (NCT01640314) | Novartis Vaccines | 2012-07-01 |
| A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1 (NCT01623518) | University of Oxford | 2012-06-01 |
| Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents (NCT01609998) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-06-01 |
| Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine (NCT01617239) | Crucell Holland BV | 2012-06-01 |
| Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine (NCT01625689) | PATH Vaccine Solutions | 2012-06-01 |
| Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years (NCT01560793) | VaxInnate Corporation | 2012-06-01 |
| H5N1 Vaccination With and Without AS03: Systems Biology Analysis (NCT01573312) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-05-24 |
| Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization (NCT02987374) | Stanford University | 2012-05-01 |
| Influenza Immunization of Children in India (NCT01680679) | University of Colorado, Denver | 2012-05-01 |
| Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (NCT01612000) | Protein Sciences Corporation | 2012-05-01 |
| A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults (NCT01579916) | MedImmune LLC | 2012-05-01 |
| Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada (NCT01683630) | International Centre for Infectious Diseases, Canada | 2012-04-01 |
| Banlangen Granules Anti-seasonal Influenza Study (NCT02232945) | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited | 2012-04-01 |
| Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine (NCT01507779) | PATH | 2012-04-01 |
| Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine (NCT01580033) | Jiangsu Province Centers for Disease Control and Prevention | 2012-04-01 |
| Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (NCT01578317) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-03-20 |
| A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults (NCT01561768) | Novavax | 2012-03-01 |
| The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (NCT01551810) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2012-03-01 |
| The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug） (NCT01551823) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2012-03-01 |
| Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults (NCT01481454) | Sanofi Pasteur, a Sanofi Company | 2012-03-01 |